(19)
(11) EP 4 153 192 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.09.2024 Bulletin 2024/36

(45) Mention of the grant of the patent:
24.07.2024 Bulletin 2024/30

(21) Application number: 21725557.9

(22) Date of filing: 19.05.2021
(51) International Patent Classification (IPC): 
A61K 33/26(2006.01)
A61P 29/00(2006.01)
A61P 39/04(2006.01)
A61K 39/395(2006.01)
A61P 37/02(2006.01)
C07K 16/28(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 33/26; C07K 16/2884; A61P 29/00; A61P 37/02; A61P 39/04; C07K 2317/76; C07K 2317/24; G01N 33/53; G01N 2333/70585; G01N 2800/7057; G01N 2800/50; G01N 2333/165
(86) International application number:
PCT/EP2021/063224
(87) International publication number:
WO 2021/233962 (25.11.2021 Gazette 2021/47)

(54)

ANTAGONIST OF CD44/HYALURONIC ACID PATHWAY FOR USE IN A METHOD FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME

ANTAGONIST DES CD44/HYALURONSÄURE-WEGS ZUR VERWENDUNG IN EINEM VERFAHREN ZUR BEHANDLUNG DES ZYTOKINFREISETZUNGSSYNDROMS

ANTAGONISTE DE LA VOIE CD44/ACIDE HYALURONIQUE POUR UTILISATION DANS UNE MÉTHODE DE TRAITEMENT DU SYNDROME DE LIBÉRATION DE CYTOKINES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 19.05.2020 EP 20305520

(43) Date of publication of application:
29.03.2023 Bulletin 2023/13

(60) Divisional application:
24184659.1 / 4424711

(73) Proprietors:
  • Institut Curie
    75005 Paris (FR)
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
    75013 Paris (FR)
  • Centre National de la Recherche Scientifique
    75016 Paris (FR)

(72) Inventors:
  • RODRIGUEZ, Raphaël
    75005 PARIS (FR)
  • MULLER, Sebastian
    75005 Paris (FR)
  • SOLIER, Stéphanie
    75005 PARIS (FR)
  • WATSON, Sarah
    75005 PARIS (FR)

(74) Representative: Cabinet Becker et Associés 
25, rue Louis le Grand
75002 Paris
75002 Paris (FR)


(56) References cited: : 
   
  • CARLO PERRICONE ET AL: "COVID-19 as part of the hyperferritinemic syndromes: is there a role for iron depletion therapy?", AUTHOREA, INC., 6 May 2020 (2020-05-06), XP055747429, Retrieved from the Internet <URL:https://d197for5662m48.cloudfront.net/documents/publicationstatus/35416/preprint_pdf/91503dd383420308c403046292845e4c.pdf> DOI: 10.22541/au.158880283.34604328
  • DALAMAGA MARIA ET AL: "Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 108, 8 May 2020 (2020-05-08), XP086199072, ISSN: 0026-0495, [retrieved on 20200508], DOI: 10.1016/J.METABOL.2020.154260
  • SEBASTIAN MÜLLER ET AL: "CD44 regulates epigenetic plasticity by mediating iron endocytosis", BIORXIV, 9 July 2019 (2019-07-09), XP055747098, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/693424v1.full.pdf> [retrieved on 20201104], DOI: 10.1101/693424
  • HERBERT A. RUNNELS ET AL: "PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases", ADVANCES IN THERAPY., vol. 27, no. 3, 1 March 2010 (2010-03-01), US, pages 168 - 180, XP055747387, ISSN: 0741-238X, DOI: 10.1007/s12325-010-0010-0
  • SHI YUFANG ET AL: "COVID-19 infection: the perspectives on immune responses", CELL DEATH & DIFFERENTIATION, NATURE PUBLISHING GROUP, GB, vol. 27, no. 5, 23 March 2020 (2020-03-23), pages 1451 - 1454, XP037098196, ISSN: 1350-9047, [retrieved on 20200323], DOI: 10.1038/S41418-020-0530-3
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).